We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drug Industry Considers Training, Fact Sheets for Opioid REMS
Drug Industry Considers Training, Fact Sheets for Opioid REMS
May 28, 2009
A working group of 25 brand- and generic-drug makers is considering whether proposed risk evaluation and mitigation strategies (REMS) for certain opioid products should require healthcare provider certification in addition to fact sheets and medication guides for patients, a representative said at an FDA public meeting.